Dr Reddy s initiates process for emergency use authorisation of Sputnik V ANI | Updated: Feb 19, 2021 15:39 IST
As part of the review process, Dr Reddy s will present the safety profile of phase two study and interim data of phase three study which is expected to complete by February 21. The efficacy of Sputnik V was reported to be 91.6 per cent by the Lancet, which is an impressive development in the fight against Covid-19, said Co-chairman and Managing Director G V Prasad. The initiation of the emergency use authorisation process will be a critical step forward for us in ensuring speedy access to the Sputnik V vaccine in India, he said in a statement.
Pharma major Dr. Reddy s Laboratories Ltd on Friday announced that it has initiated the process with the Drugs Controller General of India (DCGI) for Emergency Use Authorization (EUA) of the well-studied human adenoviral vector-based platform .
URL copied
Dr Reddy s begins process to obtain emergency use authorisation for Sputnik V
Dr Reddy s Laboratories on Friday said it has approached drugs regulator DCGI for emergency use authorisation (EUA) for COVID-19 vaccine Sputnik V. As part of the review process, the drug major will present the safety profile of phase 2 study, and interim data of phase 3 trial, which is expected to be complete by February 21, 2021, Dr Reddy s said in a statement.
In September last year, the Hyderabad-based firm partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and for its distribution rights in India.
Dr.Reddy s gets authorisation to start rolling out Sputnik V COVID-19 vaccine in India
IANSFeb 19, 2021, 17:58 IST
TOI
Hyderabad, Feb Pharma major Dr. Reddy s Laboratories Ltd on Friday announced that it has initiated the process with the
Drugs Controller General of India (
DCGI) for Emergency Use Authorization (
EUA) of the well-studied human adenoviral vector-based platform vaccine candidate,
Sputnik V.
As part of the review process, Dr. Reddy s will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by February 21, the Hyderabad-based firm said. Dr. Reddy s partnered with the Russian Direct Investment Fund (
Dr Reddy s to seek emergency use authorisation for Russia s Sputnik V in India
As part of the review process, Dr Reddy s will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 21st February 2021.
BusinessToday.In | February 19, 2021 | Updated 15:48 IST
Sputnik V maintained a consistent efficacy at 91.8 per cent even among the group of 2,144 volunteers over 60 years old, Dr Reddy s said.
Drug firm Dr Reddy s Laboratories on Friday said it has initiated the process with the Drugs Controller General of India (DCGI) for emergency use authorisation (EUA) for Russia s Sputnik V vaccine against COVID-19.